Helen Yu

Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study

Structural basis for mismatch surveillance by CRISPR–Cas9

Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent

DNA Unwinding Is the Primary Determinant of CRISPR-Cas9 Activity